查看購物車
  • Simplified Chinese
  • English
  • Japanese
生物製藥研發市場－全球及區域分析：依方法、生產類型、類型及地區分類－分析與預測（2025-2035）
市場調查報告書
商品編碼
1871069

生物製藥研發市場－全球及區域分析：依方法、生產類型、類型及地區分類－分析與預測（2025-2035）

Biologics Drug Discovery Market - A Global and Regional Analysis: Focus on Method, Manufacturing Type, Type, and Region - Analysis and Forecast, 2025-2035
出版日期: | 出版商: BIS Research | 英文 189 Pages | 商品交期: 1-5個工作天內

價格

這份報告可以在一個工作天內送達。

生物製藥研發市場簡介

2024年全球生物製藥研發市場規模為213.4億美元，預計到2035年將顯著成長至630.7億美元，2025年至2035年的複合年成長率將達到10.38%。

關鍵市場統計數據
預測期 2025-2035
截至2025年的估值 234.9億美元
2035 年預測 630.7億美元
複合年成長率 10.38%

生物製藥研發市場正經歷穩定成長，這主要得益於慢性病和罕見疾病病例的增加、對精準標標靶治療的需求不斷成長以及治療策略向更有效的作用機制導向型治療方法的轉變。單株抗體、重組蛋白和新一代療法等生物製劑因其優於傳統小分子化合物的選擇性和治療效果而備受關注。政府支持的研發資金、公私合營以及有利的法規結構等扶持措施，進一步加速了創新，並擴大了生物製劑在腫瘤學、免疫學和神經病學等治療領域的應用。

快速的技術進步也正在改變生物製藥研發的格局，人工智慧輔助標靶辨識、高通量篩檢、單細胞分析和抗體工程等技術提高了早期研發的效率和成功率。儘管取得了這些進展，但高昂的研發成本、複雜的生產流程以及研究基礎設施和人才的區域差異等挑戰仍然是規模化生產的重要障礙。然而，持續的全球投資、不斷擴展的外包模式以及對個人化醫療日益成長的需求，預計將在未來十年內將生物製藥研發打造成為下一代治療創新的基石。

市場介紹

在藥物發現平台和策略聯盟的持續創新驅動下，生物製藥研發市場正經歷重大變革。各公司積極採用高通量篩檢、人工智慧驅動的藥物發現平台和先進的抗體庫等尖端技術，以提高治療藥物研發的速度和準確性。 Alloy Therapeutics 的 mAbForge 高通量篩檢服務、百奧賽圖製藥（北京）有限公司的 RenBiologics 抗體平台以及 Evotec SE 的 J.CHO 超表達系統等知名產品的推出，體現了業界對提高生物製劑研發效率和擴充性的重視。隨著生物製藥在滿足腫瘤學、免疫學和罕見疾病領域未被滿足的臨床需求方面的重要性日益凸顯，這些創新有望重塑藥物研發格局，並將生物製藥定位為下一代治療藥物研發的基石。

對產業的影響

在精準標靶治療需求不斷成長以及個人化醫療日益受到重視的推動下，全球生物製藥研發市場正經歷著深刻的變革時期。 Alloy Therapeutics、Charles River Laboratories International、Regeneron Pharmaceuticals 和 WuXi Biologics (Cayman) Inc. 等主要企業在推動生物製藥研發技術方面發揮著核心作用，支持著超越傳統療法的新型治療方法的開發。這些創新在腫瘤學、免疫學和罕見疾病等領域至關重要，能夠實現更有效率、更具針對性的藥物研發，並改善治療效果。透過提高候選藥物辨識的速度和準確性、降低研發成本以及促進全球合作，生物製藥研發有助於建立更有效率、更精簡的治療方案開發流程。生物製劑生物製藥研發與全球精準醫療的轉型相契合，進一步增強了其市場影響力，使其成為下一代治療進步的基石。

市場區隔:

類別 1：依方法

  • 目標識別與檢驗
  • 命中創建/檢驗
  • 先導化合物鑑定
  • 先導藥物最適化

先導化合物的發現/檢驗推動了生物製藥發現市場（按方法分類）

依方法論分類，全球生物製藥研發市場將以先導化合物發現/檢驗主導，預計到2024年將佔28.8%的市場佔有率。該領域在生物製藥開發的早期階段至關重要，因為識別潛在的候選藥物（例如抗體療法）對於治療計畫的成功至關重要。目前應用最廣泛的先導化合物發現/檢驗方法包括噬菌體展示篩檢和融合瘤篩檢，這兩種方法對於產生和檢驗高親和性抗體都至關重要。噬菌體展示技術能夠快速篩檢大型抗體庫以識別特定的候選藥物，而融合瘤篩檢仍是單株抗體生產的基礎。隨著精準醫療需求的不斷成長，這些方法對於發現新的生物製藥至關重要，尤其是在癌症和自體免疫疾病等複雜疾病的治療方面。先進技術的日益普及反映了它們在加速生物製藥藥物研發進程和推動市場持續成長方面的重要作用。

細分2：依生產類型

  • 內部生產
  • 外包委託製造

內部生產是生物製藥研發市場的主要驅動力（按生產類型分類）。

按生產類型分類，內部生產在生物製藥研發市場中佔據主導地位，預計到2024年將佔65.3%的市場佔有率。由於在品管、智慧財產權保護和成本管理方面具有優勢，內部生產仍然是首選方法。然而，隨著越來越多的公司尋求降低營運成本、提高擴充性並獲取專業知識，預計從2025年到2035年，外包生產市場將以11.2%的複合年成長率成長。外包使公司能夠利用合約生產組織（CMO）提供的契約製造技術，例如高通量篩檢和大規模生物製藥生產，而無需大量資本投資。隨著中小型生物技術和製藥公司越來越依賴外部合作夥伴進行生物製藥（包括單株抗體、重組蛋白以及細胞和基因療法）的發現、開發和生產，這種轉變尤其明顯。生物製藥需求的不斷成長，以及生產流程對靈活性和效率的更高要求，預計將推動外包產業的持續成長，而外包產業有望成為生物製藥研發市場擴張的重要因素。

細分3：按類型

  • 單株抗體
  • 重組蛋白
  • 其他生物製藥

其他推動生物製藥生物製藥（按類型分類）

按類型分類，全球生物製藥研發市場將由其他生物製藥細分市場主導，預計到2024年將佔據43.8%的市場佔有率。該細分市場的主導地位歸功於對創新治療方法和治療策略的日益重視，例如個人化醫療、免疫療法和先進疫苗的研發。疫苗需求的激增，尤其是在全球健康危機之後，加速了疫苗生產和研發的步伐。同樣，旨在解決以往難以治癒的遺傳疾病的細胞和基因療法的快速發展，也引起了公共和私營部門的廣泛關注。此外，對包括幹細胞和基因編輯技術在內的細胞療法研發投入的不斷增加，預計將推動該細分市場的持續成長。此類別治療方法的多樣性，加上慢性病和遺傳病患疾病率的上升，使得其他生物製藥細分市場成為整個生物製藥市場的關鍵驅動力。

細分 4：按地區

  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 其他
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 其他
  • 其他地區

預計亞太地區將在生物製藥研發市場中實現最高的區域成長率。

預計2025年至2035年預測期內，亞太地區生物製藥研發市場將以11.9%的顯著速度成長。這一快速成長主要受以下幾個關鍵因素驅動：生物技術研發投入的增加、醫療基礎設施的不斷完善以及對個人化醫療日益成長的關注。亞太地區醫療衛生體系多元化且發展迅速，生物製劑領域正取得顯著進展。各國政府和私人機構，特別是中國、日本、印度和韓國等國家，正大力投資生物製藥研發。該地區人口眾多且老化嚴重，加上癌症、糖尿病和自體免疫疾病等慢性病負擔日益加重，迫切需要創新型生物療法。此外，CRISPR和基因編輯等尖端技術的日益普及，以及細胞和基因療法的進步，預計將進一步鞏固該地區在生物製藥研發領域的領先地位。亞太市場也受益於人們對生物相似藥日益成長的關注，因為生物相似藥是昂貴的生物療法的經濟有效的替代品，這使得全部區域更廣泛的患者群體更容易獲得這些治療方法。

生物製藥研發市場的最新趨勢

  • 2025 年 6 月，艾伯維公司收購了 Capstan Therapeutics 公司，以利用該公司的標靶脂質奈米顆粒 (tLNP) 平台，推進自體免疫疾病的 CAR-T 療法的開發。
  • 2025 年 1 月，Evotec SE 與延世大學和韓國生物技術公司 Zymedi 合作，獲得了韓國先進技術研究院 (KIAT) 450 萬美元的津貼，用於開發治療氣喘和特發性肺纖維化 (IPF) 等肺部疾病的First-in-Class生物療法。
  • 2024 年 1 月，百奧賽圖醫藥（北京）有限公司推出子品牌“RenBiologics”，致力於授權其全人源抗體庫和 RenMice 藥物發現平台，從而實現全球夥伴關係和基於抗體的療法的共同開發。

需求——促進因素、挑戰與機遇

市場促進因素

慢性病和罕見疾病病例增加推動生物製劑需求—對慢性病和罕見疾病創新治療方法的需求日益成長，推動了創新生物製劑的需求及其研發。癌症、自體免疫疾病和心血管疾病等慢性病持續為全球醫療保健系統帶來挑戰。能夠針對特定分子路徑的生物製劑為這些複雜疾病提供了有效的解決方案。此外，罕見疾病的盛行率不斷上升，而這些疾病往往缺乏有效的治療方法，這進一步凸顯了生物製藥在滿足未被滿足的醫療需求方面的重要性。單株抗體、重組蛋白、基因療法和酵素替代療法等治療方法在治療這些疾病方面發揮主導作用。隨著全球醫療保健格局的演變和對先進標靶治療方法需求的增加，新型生物製藥的發現有望在塑造醫療保健的未來方面發揮關鍵作用。

市場挑戰

高昂的研發和生產成本－生物製藥的發現、開發和生產高成本，對市場成長構成重大挑戰。生物製藥，尤其是處於研發或後期開發階段的生物製劑，需要在研究、生產和品管方面投入大量資金。這些流程複雜且資源密集，通常涉及最尖端科技、專用設施和嚴格的監管要求。因此，生物製藥往往比傳統小分子藥物更昂貴，限制了其可近性，尤其是在資源有限或對成本敏感的醫療環境中。此外，生物療法的高昂價格，加上持續研發的需求，給醫療系統和患者帶來了經濟壓力。這些經濟障礙限制了服務不足地區和經濟困難人口獲得生物製藥的機會。克服這些挑戰對於推進生物製藥研發、擴大生物療法的覆蓋範圍以及確保其在各種醫療環境中得到更廣泛的應用至關重要。

市場機遇

人工智慧在生物製藥研發中的應用－將人工智慧（AI）融入生物製藥藥物研發流程，可望大幅提升生物療法的研發速度、效率和成本效益，從而帶來巨大的發展機會。包括機器學習和深度學習在內的人工智慧技術，能夠更精準地預測分子交互作用，最佳化藥物設計，並簡化新型生物製藥。北美和歐洲等專注於創新和先進醫療技術的地區，在將人工智慧融入生物製藥研發方面取得了顯著進展。此外，生物製藥公司與人工智慧技術供應商之間的合作也不斷加強，進一步提升了生物製藥藥物研發平台的能力。

全球生物製藥研發市場已根據技術、生產類型、類型、地區等各種類別進行了詳細細分。這有助於讀者清楚了解哪個細分市場佔據最大佔有率，以及未來幾年該細分市場預計將在哪些方面成長。

夥伴關係、聯盟和業務擴張是主要發展趨勢，約佔 2022 年 1 月至 2025 年 9 月全球生物製藥發現市場所有趨勢的 74%。

競爭策略：全球生物製藥研發市場由眾多擁有豐富產品系列的成熟企業所組成。本研究分析介紹的全球生物製藥研發市場主要企業包括提供生物製藥研發平台、產品和服務的知名公司。

主要市場參與企業及競爭摘要

目標公司的選擇依據是公司概況、產品系列和市場滲透率的分析所收集的資訊。

該市場的主要企業包括：

  • Alloy Therapeutics, Inc.
  • Charles River Laboratories International, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • WuXi Biologics (Cayman) Inc.
  • AbbVie Inc.
  • Amgen, Inc.
  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • Bristol-Myers Squibb
  • Novo Nordisk A/S
  • Novartis AG
  • Evotec SE
  • Eli Lilly and Company
  • GenScript Biotech Corporation
  • Gilead Sciences, Inc.
  • Merck KGaA
  • Johnson & Johnson
  • Pfizer, Inc.
  • F. Hoffmann-La Roche AG

目錄

執行摘要

第1章 全球生物製藥研發市場：產業展望

  • 市場概覽
  • 主要市場趨勢
    • 雙特異性和多特異性抗體研發進展
    • 加強夥伴關係與合作
    • 對外包服務的需求不斷成長
  • 監管狀態
    • 美國
    • 歐洲
    • 亞太地區
    • 其他地區
  • 供應鏈分析
    • 供應鍊及其風險
  • 專利分析
  • 市場動態
    • 市場促進因素
    • 市場挑戰
    • 市場機遇

2. 2023-2035年全球生物製藥研發市場（依方法論分類）

  • 目標識別/檢驗
    • 功能基因體學/蛋白質體學
    • 基於細胞的檢測
    • CRISPR/基因敲除研究/Cas9
    • 動物/疾病模型
    • 計算科學/In Silico/生物資訊學
  • 命中率產生/檢驗
    • mAb定序
    • 融合瘤篩檢
    • 客製化合成資料庫篩選
    • 噬菌體展示篩檢
    • 高通量篩檢
    • 其他
  • 鉛識別
    • 噬菌體展示
    • ELISA/ADCC 和 CDC 檢測
    • 基於陣列的篩檢
    • 融合瘤篩檢及人源化
    • 生物分析
    • 其他檢測
  • 先導藥物最適化
    • 人性化
    • 親和性分析
    • 蛋白質工程
    • 體外/體內功效試驗
    • 其他

3. 2023-2035年全球生物製藥研發市場（依生產類型分類）

  • 內部生產
  • 外包製造

4. 2023-2035年全球生物製藥研發市場（依類型分類）

  • 單株抗體
  • 重組蛋白
  • 其他

5. 2023-2035年全球生物製藥研發市場（按地區分類）

  • 北美洲
  • 歐洲
  • 亞太地區
  • 其他地區

第6章 競爭基準化分析與公司概況

  • 各公司的主要策略和發展
  • 公司簡介
    • Alloy Therapeutics, Inc.
    • AbbVie Inc.
    • Amgen, Inc.
    • Astellas Pharma Inc.
    • AstraZeneca Plc
    • Charles River Laboratories International, Inc.
    • Eli Lilly and Company
    • Evotec SE
    • F. Hoffmann-La Roche AG
    • GenScript Biotech Corporation
    • Gilead Sciences, Inc.
    • Johnson & Johnson
    • Merck KGaA
    • Novo Nordisk A/S
    • Novartis AG
    • Pfizer, Inc.
    • Regeneron Pharmaceuticals, Inc.
    • WuXi Biologics (Cayman) Inc.

第7章調查方法

Product Code: BHP0493SB

This report can be delivered within 1 working day.

Introduction of the Biologics Drug Discovery Market

The global biologics drug discovery market, initially valued at $21.34 billion in 2024, is projected to witness substantial growth, surging to $63.07 billion by 2035, marking a remarkable compound annual growth rate (CAGR) of 10.38% over the period from 2025 to 2035.

KEY MARKET STATISTICS
Forecast Period2025 - 2035
2025 Evaluation$23.49 Billion
2035 Forecast$63.07 Billion
CAGR10.38%

The biologics drug discovery market has been witnessing steady growth, driven by the rising prevalence of chronic and rare diseases, increasing demand for precision-targeted therapies, and the shift toward more effective mechanism-based treatments. Biologics such as monoclonal antibodies, recombinant proteins, and next-generation therapies are gaining traction due to their ability to deliver higher selectivity and therapeutic efficacy compared to traditional small molecules. Supportive initiatives, including government-backed R&D funding, public-private collaborations, and favorable regulatory frameworks, are further accelerating innovation and expanding adoption across therapeutic areas such as oncology, immunology, and neurology.

Rapid technological advances are also reshaping the biologics drug discovery landscape, with AI-driven target identification, high-throughput screening, single-cell analysis, and antibody engineering enhancing efficiency and success rates in early-stage development. Despite these tailwinds, challenges such as high development costs, complex manufacturing processes, and regional disparities in research infrastructure and talent remain significant barriers to scale. Nevertheless, continued global investment, expanding outsourcing models, and growing demand for personalized medicine are expected to establish biologics drug discovery as a cornerstone of next-generation therapeutic innovation over the coming decade.

Market Introduction

The biologics drug discovery market has been undergoing a significant transformation, driven by continuous innovation in discovery platforms and strategic partnerships. Companies are increasingly adopting cutting-edge technologies such as high-throughput screening, AI-driven discovery platforms, and advanced antibody libraries to enhance the speed and precision of therapeutic development. Notable product launches, including Alloy Therapeutics, Inc.'s mAbForge high-throughput screening service, Biocytogen Pharmaceuticals (Beijing) Co., Ltd.'s RenBiologics antibody platform, and Evotec SE's J.CHO High Expression System for continuous antibody manufacturing, reflect the industry's focus on improving efficiency and scalability in biologics development. As biologics continue to gain prominence in addressing unmet clinical needs in oncology, immunology, and rare diseases, these innovations are poised to redefine the landscape of drug discovery, positioning biologics as a cornerstone of next-generation therapeutic development.

Industrial Impact

The global biologics drug discovery market has been experiencing a significant shift, driven by the increasing demand for precision-targeted therapies and the growing focus on personalized medicine. Key players such as Alloy Therapeutics, Inc., Charles River Laboratories International, Inc., Regeneron Pharmaceuticals, Inc., and WuXi Biologics (Cayman) Inc. have been playing a central role in advancing biologics discovery technologies, supporting the development of novel therapies beyond traditional approaches. These innovations are crucial in areas such as oncology, immunology, and rare diseases, enabling more efficient and targeted drug development with improved therapeutic outcomes. By enhancing the speed and precision of candidate identification, reducing development costs, and facilitating global partnerships, biologics drug discovery is contributing to a more effective and streamlined therapeutic development process. The market's impact is further amplified by its alignment with the global shift toward precision medicine, positioning biologics as a cornerstone of next-generation therapeutic advancements.

Market Segmentation:

Segmentation 1: By Method

  • Target Identification/Validation
  • Hit Generation/Validation
  • Lead Identification
  • Lead Optimization

Hit Generation/Validation to Dominate the Biologics Drug Discovery Market (by Method)

Based on the method, the global biologics drug discovery market was led by hit generation/validation, which held a 28.8% share in 2024. This segment is essential in the early stages of biologics development, where identifying potential drug candidates, such as antibody therapeutics, is critical for the success of therapeutic programs. Among the most widely adopted methods in hit generation/validation are phage display screening and hybridoma screening, both of which are pivotal in generating and validating high-affinity antibodies. Phage display allows for the rapid screening of large antibody libraries to identify specific candidates, while hybridoma screening continues to be a cornerstone for monoclonal antibody production. As the demand for precision medicine grows, these methods are crucial in discovering new biologics, particularly for complex diseases such as cancer and autoimmune disorders. The growing adoption of advanced technologies reflects their vital role in accelerating the biologics drug discovery process and positioning the market for sustained growth.

Segmentation 2: By Manufacturing Type

  • In-House Manufacturing
  • Outsourced Manufacturing

In-house Manufacturing to Dominate the Biologics Drug Discovery Market (by Manufacturing Type)

Based on manufacturing type, the biologics drug discovery market was led by the in-house manufacturing segment, which held a 65.3% share in 2024. In-house production remains the preferred approach due to its control over quality, intellectual property, and cost management. However, the outsourced manufacturing segment is growing at a higher annualized growth rate (CAGR) of 11.2% from 2025 to 2035, as more companies seek to reduce operational costs, increase scalability, and access specialized expertise. Outsourcing enables companies to leverage contract manufacturing organizations (CMOs) for advanced technologies, such as high-throughput screening and large-scale biologics production, without the need for heavy capital investment. This shift is particularly evident as smaller biotech firms and pharmaceutical companies increasingly rely on external partners for the discovery, development, and manufacturing of biologics, including monoclonal antibodies, recombinant proteins, and cell and gene therapies. The rising demand for biologics, coupled with the increased need for flexibility and efficiency in the manufacturing process, is expected to drive continued growth in the outsourcing sector, making it an essential component of the biologics drug discovery market's expansion.

Segmentation 3: By Type

  • Monoclonal Antibodies
  • Recombinant Proteins
  • Other Biologics

Other Biologics to Dominate the Biologics Drug Discovery Market (by Type)

Based on type, the global biologics drug discovery market was led by the other biologics segment, which held a 43.8% share in 2024. This segment's dominance can be attributed to the growing emphasis on innovative treatments and therapeutic strategies, such as personalized medicine, immunotherapies, and advanced vaccine development. The surge in demand for vaccines, particularly in the wake of global health crises, has accelerated the focus on vaccine production and research. Similarly, the rapid advancement of cell and gene therapies, which aim to address previously untreatable genetic disorders, has garnered substantial attention from both public and private sectors. Furthermore, the increased investment in the research and development of cell-based therapies, including stem cells and gene-editing technologies, is expected to drive the continued growth of this segment. The diversity of treatment approaches within this category, coupled with the rising prevalence of chronic diseases and genetic disorders, positions the other biologics segment as a key driver in the overall biologics market.

Segmentation 4: By Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest-of-Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest-of-Asia-Pacific
  • Rest-of-the-World

Asia-Pacific to Witness the Highest Growth in the Biologics Drug Discovery Market (by Region)

The biologics drug discovery market in the Asia-Pacific region is expected to witness a significant growth rate of 11.9% during the forecast period 2025-2035. This rapid expansion is driven by several key factors, including the increasing investment in biotechnology research, enhanced healthcare infrastructure, and a growing emphasis on personalized medicine. Asia-Pacific, with its diverse and rapidly evolving healthcare landscape, is witnessing significant advancements in biologics, particularly in countries including China, Japan, India, and South Korea, where governments and private organizations are heavily investing in biopharmaceutical research and development. The region's large and aging population, coupled with a rising burden of chronic diseases such as cancer, diabetes, and autoimmune disorders, has created a pressing need for innovative biologic therapies. Furthermore, the increasing adoption of cutting-edge technologies such as CRISPR and gene editing, alongside advancements in cell and gene therapies, is expected to fuel the region's dominance in biologics drug discovery. The Asia-Pacific market is also benefiting from the growing focus on biosimilars, which offer a cost-effective alternative to expensive biologic therapies, making them increasingly accessible to a wider patient base across the region.

Recent Developments in the Biologics Drug Discovery Market

  • In June 2025, AbbVie Inc. acquired Capstan Therapeutics, Inc. to advance in vivo CAR-T therapies for autoimmune diseases using Capstan's targeted lipid nanoparticle (tLNP) platform.
  • In January 2025, Evotec SE, in collaboration with Yonsei University and the Korean biotech company Zymedi, received a $4.5 million grant from the Korea Institute of Advanced Technology (KIAT) to develop first-in-class biologic therapies for lung diseases, specifically asthma and idiopathic pulmonary fibrosis (IPF).
  • In January 2024, Biocytogen Pharmaceuticals (Beijing) Co., Ltd. launched RenBiologics, a sub-brand dedicated to out-licensing its fully human antibody library and RenMice discovery platforms, enabling global partnerships and co-development for antibody-based therapeutics.

Demand - Drivers, Challenges, and Opportunities

Market Drivers

Rising Prevalence of Chronic and Rare Diseases Driving Biologics Demand: The growing need for innovative treatments in chronic and rare diseases is fueling the demand for innovative biologics and their discovery. Chronic conditions such as cancer, autoimmune disorders, and cardiovascular diseases continue to challenge healthcare systems worldwide. Biologics, with their ability to target specific molecular pathways, offer effective solutions for these complex diseases. Additionally, the increasing prevalence of rare diseases, which often lack viable treatments, further emphasizes the importance of biologics in addressing unmet medical needs. Therapies such as monoclonal antibodies, recombinant proteins, gene therapies, and enzyme replacement therapies are leading the way in treating these conditions. As the global healthcare landscape evolves and the need for advanced, targeted therapies rises, novel biologics drug discovery is anticipated to play a prominent role in shaping the future of medicine.

Market Challenges

High Development and Manufacturing Costs: The high costs associated with the drug discovery, development, and manufacturing of biologics present a significant challenge to market growth. Biologics, particularly those in the R&D phase or advanced stages of development, require substantial investment in research, production, and quality control. These processes are complex and resource-intensive, often involving cutting-edge technologies, specialized facilities, and stringent regulatory requirements. As a result, biologics tend to be more expensive than traditional small-molecule drugs, limiting their accessibility, particularly in resource-constrained or cost-sensitive healthcare environments. Additionally, the high price of biologic therapies, coupled with the need for ongoing research and development, places a strain on healthcare systems and patient affordability. These financial barriers limit access to biologics in underserved regions and among economically disadvantaged populations. Overcoming these challenges will be essential for advancing biologics drug discovery, expanding the reach of biologic treatments, and ensuring their broader adoption across diverse healthcare settings.

Market Opportunities

AI Integration in Biologics Drug Discovery: The integration of artificial intelligence (AI) into biologics drug discovery presents a significant growth opportunity, driven by the potential for faster, more efficient, and cost-effective development of biologic therapies. AI technologies, including machine learning and deep learning, are enabling more accurate prediction of molecular interactions, optimizing drug design, and streamlining the discovery of novel biologic candidates. As AI continues to evolve, its ability to analyze vast datasets, such as genetic information, clinical trial data, and protein structures, has the potential to accelerate the identification of high-potential drug targets and improve the precision of biologics development. In regions including North America and Europe, where there is a strong focus on innovation and advanced healthcare technologies, AI integration in biologics drug discovery is gaining traction. Additionally, collaborations between biopharma companies and AI technology providers are increasing, further enhancing the capabilities of biologics drug discovery platforms.

How can this report add value to an organization?

Product/Innovation Strategy: The global biologics drug discovery market has been extensively segmented based on various categories, such as method, manufacturing type, type, and region. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.

Growth/Marketing Strategy: Partnerships, alliances, and business expansions have accounted for the majority of key developments, comprising nearly 74% of the total developments in the global biologics drug discovery market between January 2022 and September 2025.

Competitive Strategy: The global biologics drug discovery market has numerous established players with product portfolios. Key players in the global biologics drug discovery market, analyzed and profiled in the study, include established players offering platforms, products, and services for biologics drug discovery.

Methodology

Key Considerations and Assumptions in Market Engineering and Validation

  • Years from 2023 to 2035 have been considered for the global market size estimation, 2024 has been considered as the base year, and 2025 to 2035 as the forecast period.
  • The scope of this report has been carefully developed based on insights from experts across various companies worldwide. It presents a comprehensive market study of the platforms, products, and services within the biologics drug discovery market.
  • The market contribution of biologics drug discovery is anticipated to grow substantially in the future, with projections based on historical analysis of available solutions.
  • Revenues from companies have been sourced from their annual reports for FY2023 and FY2024. For private companies, revenue estimates are derived from primary research inputs, funding history, market collaborations, and operational performance.
  • The market has been mapped based on the existing biologics drug discovery platforms, products, and services. Key companies with significant offerings in this field have been identified and profiled in this report.

Primary Research

The primary sources involve industry experts in biologics drug discovery, including the market players offering products and services. Resources such as CEOs, vice presidents, marketing directors, and technology and innovation directors have been interviewed to obtain and verify both qualitative and quantitative aspects of this research study.

The key data points taken from the primary sources include:

  • validation and triangulation of all the numbers and graphs
  • validation of report segmentations and key qualitative findings
  • understanding the competitive landscape and business model
  • current and proposed production values of a product by market players
  • validation of the numbers of different segments of the market in focus
  • percentage split of individual markets for regional analysis

Secondary Research

Open Sources

  • Certified publications, articles from recognized authors, white papers, directories, and major databases, among others
  • Annual reports, SEC filings, and investors' presentations of the leading market players
  • Company websites and a detailed study of their product portfolio
  • Gold standard magazines, journals, white papers, press releases, and news articles
  • Paid databases

The key data points taken from the secondary sources include:

  • segmentations and percentage shares
  • data for market value
  • key industry trends of the top players in the market
  • qualitative insights into various aspects of the market, key trends, and emerging areas of innovation
  • quantitative data for mathematical and statistical calculations

Key Market Players and Competition Synopsis

The companies profiled have been selected based on inputs gathered from an analysis of company coverage, product portfolio, and market penetration.

Some prominent names established in this market are:

  • Alloy Therapeutics, Inc.
  • Charles River Laboratories International, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • WuXi Biologics (Cayman) Inc.
  • AbbVie Inc.
  • Amgen, Inc.
  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • Bristol-Myers Squibb
  • Novo Nordisk A/S
  • Novartis AG
  • Evotec SE
  • Eli Lilly and Company
  • GenScript Biotech Corporation
  • Gilead Sciences, Inc.
  • Merck KGaA
  • Johnson & Johnson
  • Pfizer, Inc.
  • F. Hoffmann-La Roche AG

Table of Contents

Executive Summary

Scope and Definition

1 Global Biologics Drug Discovery Market: Industry Outlook

  • 1.1 Market Overview
  • 1.2 Key Market Trends
    • 1.2.1 Growth of Bispecific and Multispecific Antibody Development
    • 1.2.2 Rising Partnerships and Collaborations
    • 1.2.3 Rising Demand for Outsourcing Services
  • 1.3 Regulatory Landscape
    • 1.3.1 U.S.
    • 1.3.2 Europe
      • 1.3.2.1 Germany
      • 1.3.2.2 France
      • 1.3.2.3 Italy
    • 1.3.3 Asia-Pacific
      • 1.3.3.1 China
      • 1.3.3.2 Japan
    • 1.3.4 Rest-of-the-World
  • 1.4 Supply Chain Analysis
    • 1.4.1 Supply Chain and Risks within the Supply Chain
  • 1.5 Patent Analysis
    • 1.5.1 Patent Filing Trend (by Country)
    • 1.5.2 Patent Filing Trend (by Year)
  • 1.6 Market Dynamics
    • 1.6.1 Market Drivers
      • 1.6.1.1 Rising Prevalence of Chronic and Rare Diseases Driving Demand for Biologics in Treatment
      • 1.6.1.2 Strong Investment and R&D Funding Leading to Increased Demand for Biologics
    • 1.6.2 Market Challenges
      • 1.6.2.1 High Development and Manufacturing Costs Hindering the Growth of the Market
    • 1.6.3 Market Opportunities
      • 1.6.3.1 AI Integration in Biologics Discovery

2 Global Biologics Drug Discovery Market (by Method), ($Billion), 2023-2035

  • 2.1 Target Identification/Validation
    • 2.1.1 Functional Genomics/Proteomics
    • 2.1.2 Cell-Based Assay
    • 2.1.3 CRISPR/Knockout Studies/Cas9
    • 2.1.4 Animal/Disease-Based Models
    • 2.1.5 Computational/In-Silico/Bioinformatics
  • 2.2 Hit Generation/Validation
    • 2.2.1 mAb Sequencing
    • 2.2.2 Hybridoma Screening
    • 2.2.3 Customized Synthetic Library Screening
    • 2.2.4 Phage Display Screening
    • 2.2.5 High-Throughput Screening
    • 2.2.6 Others
  • 2.3 Lead Identification
    • 2.3.1 Phage Display
    • 2.3.2 ELISA/ADCC and CDC Assay
    • 2.3.3 Array-Based Screening
    • 2.3.4 Hybridoma Screening and Humanization
    • 2.3.5 Bioanalytical Analysis
    • 2.3.6 Other Assays
  • 2.4 Lead Optimization
    • 2.4.1 Humanization
    • 2.4.2 Affinity Analysis
    • 2.4.3 Protein Engineering
    • 2.4.4 In-Vitro/In-Vivo Efficacy Assays
    • 2.4.5 Others

3 Global Biologics Drug Discovery Market (by Manufacturing Type), ($Billion), 2023-2035

  • 3.1 In-House Manufacturing
  • 3.2 Outsourced Manufacturing

4 Global Biologics Drug Discovery Market (by Type), ($Billion), 2023-2035

  • 4.1 Monoclonal Antibodies
    • 4.1.1 Monoclonal Antibodies Drug Discovery Market, by Method
      • 4.1.1.1 Monoclonal Antibodies Drug Discovery Market, by Method, Target Identification/Validation
      • 4.1.1.2 Monoclonal Antibodies Drug Discovery Market, by Method, Hit Generation/Validation
      • 4.1.1.3 Monoclonal Antibodies Drug Discovery Market, by Method, Lead Identification
      • 4.1.1.4 Monoclonal Antibodies Drug Discovery Market, by Method, Lead Optimization
  • 4.2 Recombinant Proteins
    • 4.2.1 Recombinant Proteins Drug Discovery Market, by Method
      • 4.2.1.1 Recombinant Proteins Drug Discovery Market, by Method, Target Identification/Validation
      • 4.2.1.2 Recombinant Proteins Drug Discovery Market, by Method, Hit Generation/Validation
      • 4.2.1.3 Recombinant Proteins Drug Discovery Market, by Method, Lead Identification
      • 4.2.1.4 Recombinant Proteins Drug Discovery Market, by Method, Lead Optimization
  • 4.3 Other Biologics

5 Global Biologics Drug Discovery Market (by Region), ($Billion), 2023-2035

  • 5.1 North America
    • 5.1.1 Regional Overview
    • 5.1.2 Driving Factors for Market Growth
    • 5.1.3 Factors Challenging the Market
    • 5.1.4 Market Sizing and Forecast
      • 5.1.4.1 North America Biologics Drug Discovery Market, by Manufacturing Type
      • 5.1.4.2 North America Biologics Drug Discovery Market, by Type
      • 5.1.4.3 North America Biologics Drug Discovery Market, by Country
        • 5.1.4.3.1 U.S.
          • 5.1.4.3.1.1 Country Overview
          • 5.1.4.3.1.2 Driving Factors for Market Growth
          • 5.1.4.3.1.3 Factors Challenging the Market
          • 5.1.4.3.1.4 Market Sizing and Forecast
          • 5.1.4.3.1.4.1 U.S. Biologics Drug Discovery Market, by Manufacturing Type
          • 5.1.4.3.1.4.2 U.S. Biologics Drug Discovery Market, by Type
        • 5.1.4.3.2 Canada
          • 5.1.4.3.2.1 Country Overview
          • 5.1.4.3.2.2 Driving Factors for Market Growth
          • 5.1.4.3.2.3 Factors Challenging the Market
          • 5.1.4.3.2.4 Market Sizing and Forecast
          • 5.1.4.3.2.4.1 Canada Biologics Drug Discovery Market, by Manufacturing Type
          • 5.1.4.3.2.4.2 Canada Biologics Drug Discovery Market, by Type
  • 5.2 Europe
    • 5.2.1 Regional Overview
    • 5.2.2 Driving Factors for Market Growth
    • 5.2.3 Factors Challenging the Market
    • 5.2.4 Market Sizing and Forecast
      • 5.2.4.1 Europe Biologics Drug Discovery Market, by Manufacturing Type
      • 5.2.4.2 Europe Biologics Drug Discovery Market, by Type
      • 5.2.4.3 Europe Biologics Drug Discovery Market, by Country
        • 5.2.4.3.1 Germany
          • 5.2.4.3.1.1 Country Overview
          • 5.2.4.3.1.2 Driving Factors for Market Growth
          • 5.2.4.3.1.3 Factors Challenging the Market
          • 5.2.4.3.1.4 Market Sizing and Forecast
          • 5.2.4.3.1.4.1 Germany Biologics Drug Discovery Market, by Manufacturing Type
          • 5.2.4.3.1.4.2 Germany Biologics Drug Discovery Market, by Type
        • 5.2.4.3.2 U.K.
          • 5.2.4.3.2.1 Country Overview
          • 5.2.4.3.2.2 Driving Factors for Market Growth
          • 5.2.4.3.2.3 Factors Challenging the Market
          • 5.2.4.3.2.4 Market Sizing and Forecast
          • 5.2.4.3.2.4.1 U.K. Biologics Drug Discovery Market, by Manufacturing Type
          • 5.2.4.3.2.4.2 U.K. Biologics Drug Discovery Market, by Type
        • 5.2.4.3.3 France
          • 5.2.4.3.3.1 Country Overview
          • 5.2.4.3.3.2 Driving Factors for Market Growth
          • 5.2.4.3.3.3 Factors Challenging the Market
          • 5.2.4.3.3.4 Market Sizing and Forecast
          • 5.2.4.3.3.4.1 France Biologics Drug Discovery Market, by Manufacturing Type
          • 5.2.4.3.3.4.2 France Biologics Drug Discovery Market, by Type
        • 5.2.4.3.4 Italy
          • 5.2.4.3.4.1 Country Overview
          • 5.2.4.3.4.2 Driving Factors for Market Growth
          • 5.2.4.3.4.3 Factors Challenging the Market
          • 5.2.4.3.4.4 Market Sizing and Forecast
          • 5.2.4.3.4.4.1 Italy Biologics Drug Discovery Market, by Manufacturing Type
          • 5.2.4.3.4.4.2 Italy Biologics Drug Discovery Market, by Type
        • 5.2.4.3.5 Spain
          • 5.2.4.3.5.1 Country Overview
          • 5.2.4.3.5.2 Driving Factors for Market Growth
          • 5.2.4.3.5.3 Factors Challenging the Market
          • 5.2.4.3.5.4 Market Sizing and Forecast
          • 5.2.4.3.5.4.1 Spain Biologics Drug Discovery Market, by Manufacturing Type
          • 5.2.4.3.5.4.2 Spain Biologics Drug Discovery Market, by Type
        • 5.2.4.3.6 Rest-of-Europe
          • 5.2.4.3.6.1 Country Overview
          • 5.2.4.3.6.2 Driving Factors for Market Growth
          • 5.2.4.3.6.3 Factors Challenging the Market
          • 5.2.4.3.6.4 Market Sizing and Forecast
          • 5.2.4.3.6.4.1 Rest-of-Europe Biologics Drug Discovery Market, by Manufacturing Type
          • 5.2.4.3.6.4.2 Rest-of-Europe Biologics Drug Discovery Market, by Type
  • 5.3 Asia-Pacific
    • 5.3.1 Regional Overview
    • 5.3.2 Driving Factors for Market Growth
    • 5.3.3 Factors Challenging the Market
    • 5.3.4 Market Sizing and Forecast
      • 5.3.4.1 Asia-Pacific Biologics Drug Discovery Market, by Manufacturing Type
      • 5.3.4.2 Asia-Pacific Biologics Drug Discovery Market, by Type
      • 5.3.4.3 Asia-Pacific Biologics Drug Discovery Market, by Country
        • 5.3.4.3.1 China
          • 5.3.4.3.1.1 Country Overview
          • 5.3.4.3.1.2 Driving Factors for Market Growth
          • 5.3.4.3.1.3 Factors Challenging the Market
          • 5.3.4.3.1.4 Market Sizing and Forecast
          • 5.3.4.3.1.4.1 China Biologics Drug Discovery Market, by Manufacturing Type
          • 5.3.4.3.1.4.2 China Biologics Drug Discovery Market, by Type
        • 5.3.4.3.2 Japan
          • 5.3.4.3.2.1 Country Overview
          • 5.3.4.3.2.2 Driving Factors for Market Growth
          • 5.3.4.3.2.3 Factors Challenging the Market
          • 5.3.4.3.2.4 Market Sizing and Forecast
          • 5.3.4.3.2.4.1 Japan Biologics Drug Discovery Market, by Manufacturing Type
          • 5.3.4.3.2.4.2 Japan Biologics Drug Discovery Market, by Type
        • 5.3.4.3.3 India
          • 5.3.4.3.3.1 Country Overview
          • 5.3.4.3.3.2 Driving Factors for Market Growth
          • 5.3.4.3.3.3 Factors Challenging the Market
          • 5.3.4.3.3.4 Market Sizing and Forecast
          • 5.3.4.3.3.4.1 India Biologics Drug Discovery Market, by Manufacturing Type
          • 5.3.4.3.3.4.2 India Biologics Drug Discovery Market, by Type
        • 5.3.4.3.4 South Korea
          • 5.3.4.3.4.1 Country Overview
          • 5.3.4.3.4.2 Driving Factors for Market Growth
          • 5.3.4.3.4.3 Factors Challenging the Market
          • 5.3.4.3.4.4 Market Sizing and Forecast
          • 5.3.4.3.4.4.1 South Korea Biologics Drug Discovery Market, by Manufacturing Type
          • 5.3.4.3.4.4.2 South Korea Biologics Drug Discovery Market, by Type
        • 5.3.4.3.5 Australia
          • 5.3.4.3.5.1 Country Overview
          • 5.3.4.3.5.2 Driving Factors for Market Growth
          • 5.3.4.3.5.3 Factors Challenging the Market
          • 5.3.4.3.5.4 Market Sizing and Forecast
          • 5.3.4.3.5.4.1 Australia Biologics Drug Discovery Market, by Manufacturing Type
          • 5.3.4.3.5.4.2 Australia Biologics Drug Discovery Market, by Type
        • 5.3.4.3.6 Rest-of-Asia-Pacific
          • 5.3.4.3.6.1 Country Overview
          • 5.3.4.3.6.2 Driving Factors for Market Growth
          • 5.3.4.3.6.3 Factors Challenging the Market
          • 5.3.4.3.6.4 Market Sizing and Forecast
          • 5.3.4.3.6.4.1 Rest-of-Asia-Pacific Biologics Drug Discovery Market, by Manufacturing Type
          • 5.3.4.3.6.4.2 Rest-of-Asia-Pacific Biologics Drug Discovery Market, by Type
  • 5.4 Rest-of-the-World
    • 5.4.1 Regional Overview
    • 5.4.2 Driving Factors for Market Growth
    • 5.4.3 Factors Challenging the Market
    • 5.4.4 Market Sizing and Forecast
      • 5.4.4.1 Rest-of-the-World Biologics Drug Discovery Market, by Manufacturing Type
      • 5.4.4.2 Rest-of-the-World Biologics Drug Discovery Market, by Type

6 Competitive Benchmarking and Company Profiles

  • 6.1 Key Strategies and Developments by Company
    • 6.1.1 Funding Activities
    • 6.1.2 Mergers and Acquisitions
    • 6.1.3 Regulatory Approvals and Product Launches
    • 6.1.4 Partnerships, Collaborations, and Business Expansions
  • 6.2 Company Profiles
    • 6.2.1 Alloy Therapeutics, Inc.
      • 6.2.1.1 Overview
      • 6.2.1.2 Top Products/Product Portfolio
      • 6.2.1.3 Top Competitors
      • 6.2.1.4 Target Customers
      • 6.2.1.5 Key Personal
      • 6.2.1.6 Analyst View
    • 6.2.2 AbbVie Inc.
      • 6.2.2.1 Overview
      • 6.2.2.2 Top Products/Product Portfolio
      • 6.2.2.3 Top Competitors
      • 6.2.2.4 Target Customers
      • 6.2.2.5 Key Personal
      • 6.2.2.6 Analyst View
    • 6.2.3 Amgen, Inc.
      • 6.2.3.1 Overview
      • 6.2.3.2 Top Products/Product Portfolio
      • 6.2.3.3 Top Competitors
      • 6.2.3.4 Target Customers
      • 6.2.3.5 Key Personal
      • 6.2.3.6 Analyst View
    • 6.2.4 Astellas Pharma Inc.
      • 6.2.4.1 Overview
      • 6.2.4.2 Top Products/Product Portfolio
      • 6.2.4.3 Top Competitors
      • 6.2.4.4 Target Customers
      • 6.2.4.5 Key Personal
      • 6.2.4.6 Analyst View
    • 6.2.5 AstraZeneca Plc
      • 6.2.5.1 Overview
      • 6.2.5.2 Top Products/Product Portfolio
      • 6.2.5.3 Top Competitors
      • 6.2.5.4 Target Customers
      • 6.2.5.5 Key Personal
      • 6.2.5.6 Analyst View
    • 6.2.6 Charles River Laboratories International, Inc.
      • 6.2.6.1 Overview
      • 6.2.6.2 Top Products/Product Portfolio
      • 6.2.6.3 Top Competitors
      • 6.2.6.4 Target Customers
      • 6.2.6.5 Key Personal
      • 6.2.6.6 Analyst View
    • 6.2.7 Eli Lilly and Company
      • 6.2.7.1 Overview
      • 6.2.7.2 Top Products/Product Portfolio
      • 6.2.7.3 Top Competitors
      • 6.2.7.4 Target Customers
      • 6.2.7.5 Key Personal
      • 6.2.7.6 Analyst View
    • 6.2.8 Evotec SE
      • 6.2.8.1 Overview
      • 6.2.8.2 Top Products/Product Portfolio
      • 6.2.8.3 Top Competitors
      • 6.2.8.4 Target Customers
      • 6.2.8.5 Key Personal
      • 6.2.8.6 Analyst View
    • 6.2.9 F. Hoffmann-La Roche AG
      • 6.2.9.1 Overview
      • 6.2.9.2 Top Products/Product Portfolio
      • 6.2.9.3 Top Competitors
      • 6.2.9.4 Target Customers
      • 6.2.9.5 Key Personal
      • 6.2.9.6 Analyst View
    • 6.2.10 GenScript Biotech Corporation
      • 6.2.10.1 Overview
      • 6.2.10.2 Top Products/Product Portfolio
      • 6.2.10.3 Top Competitors
      • 6.2.10.4 Target Customers
      • 6.2.10.5 Key Personal
      • 6.2.10.6 Analyst View
    • 6.2.11 Gilead Sciences, Inc.
      • 6.2.11.1 Overview
      • 6.2.11.2 Top Products/Product Portfolio
      • 6.2.11.3 Top Competitors
      • 6.2.11.4 Target Customers
      • 6.2.11.5 Key Personal
      • 6.2.11.6 Analyst View
    • 6.2.12 Johnson & Johnson
      • 6.2.12.1 Overview
      • 6.2.12.2 Top Products/Product Portfolio
      • 6.2.12.3 Top Competitors
      • 6.2.12.4 Target Customers
      • 6.2.12.5 Key Personal
      • 6.2.12.6 Analyst View
    • 6.2.13 Merck KGaA
      • 6.2.13.1 Overview
      • 6.2.13.2 Top Products/Product Portfolio
      • 6.2.13.3 Top Competitors
      • 6.2.13.4 Target Customers
      • 6.2.13.5 Key Personal
      • 6.2.13.6 Analyst View
    • 6.2.14 Novo Nordisk A/S
      • 6.2.14.1 Overview
      • 6.2.14.2 Top Products/Product Portfolio
      • 6.2.14.3 Top Competitors
      • 6.2.14.4 Target Customers
      • 6.2.14.5 Key Personal
      • 6.2.14.6 Analyst View
    • 6.2.15 Novartis AG
      • 6.2.15.1 Overview
      • 6.2.15.2 Top Products/Product Portfolio
      • 6.2.15.3 Top Competitors
      • 6.2.15.4 Target Customers
      • 6.2.15.5 Key Personal
      • 6.2.15.6 Analyst View
    • 6.2.16 Pfizer, Inc.
      • 6.2.16.1 Overview
      • 6.2.16.2 Top Products/Product Portfolio
      • 6.2.16.3 Top Competitors
      • 6.2.16.4 Target Customers
      • 6.2.16.5 Key Personal
      • 6.2.16.6 Analyst View
    • 6.2.17 Regeneron Pharmaceuticals, Inc.
      • 6.2.17.1 Overview
      • 6.2.17.2 Top Products/Product Portfolio
      • 6.2.17.3 Top Competitors
      • 6.2.17.4 Target Customers
      • 6.2.17.5 Key Personal
      • 6.2.17.6 Analyst View
    • 6.2.18 WuXi Biologics (Cayman) Inc.
      • 6.2.18.1 Overview
      • 6.2.18.2 Top Products/Product Portfolio
      • 6.2.18.3 Top Competitors
      • 6.2.18.4 Target Customers
      • 6.2.18.5 Key Personal
      • 6.2.18.6 Analyst View

7 Research Methodology

  • 7.1 Data Sources
    • 7.1.1 Primary Data Sources
    • 7.1.2 Secondary Data Sources
    • 7.1.3 Data Triangulation
  • 7.2 Market Estimation and Forecast

List of Figures

  • Figure 1: Global Biologics Drug Discovery Market (by Scenario), $Billion, 2024, 2029, and 2035
  • Figure 2: Global Biologics Drug Discovery Market, 2024 and 2035
  • Figure 3: Top Countries, Global Biologics Drugs Discovery Market, $Billion, 2024
  • Figure 4: Global Biologics Drug Discovery Market, $Billion, 2025 and 2035
  • Figure 5: Global Biologics Drug Discovery Market (by Method), $Billion, 2025, 2029, and 2035
  • Figure 6: Global Biologics Drug Discovery Market (by Manufacturing Type), $Billion, 2025, 2029, and 2035
  • Figure 7: Global Biologics Drug Discovery Market (by Type), $Billion, 2025, 2029, and 2035
  • Figure 8: Number of Patents Filed (by Country), January 2021 to 12th September 2025
  • Figure 9: Number of Patents Filed (by Year), January 2021 to 12th September 2025
  • Figure 10: Incidence of Cancer (by Region), 2020-2040
  • Figure 11: Global Biologics Drug Discovery Market (by Method), $Billion, 2025, 2029, and 2035
  • Figure 12: Global Biologics Drug Discovery Market (Target Identification/Validation), $Billion, 2023-2035
  • Figure 13: Global Biologics Drug Discovery Market (Functional Genomics/Proteomics), $Billion, 2023-2035
  • Figure 14: Global Biologics Drug Discovery Market (Cell-Based Assay), $Billion, 2023-2035
  • Figure 15: Global Biologics Drug Discovery Market (CRISPR/Knockout Studies/Cas9), $Billion, 2023-2035
  • Figure 16: Global Biologics Drug Discovery Market (Animal/Disease-Based Models), $Billion, 2023-2035
  • Figure 17: Global Biologics Drug Discovery Market (Computational/In-Silico/Bioinformatics), $Billion, 2023-2035
  • Figure 18: Global Biologics Drug Discovery Market (Hit Generation/Validation), $Billion, 2023-2035
  • Figure 19: Global Biologics Drug Discovery Market (mAb Sequencing), $Billion, 2023-2035
  • Figure 20: Global Biologics Drug Discovery Market (Hybridoma Screening), $Billion, 2023-2035
  • Figure 21: Global Biologics Drug Discovery Market (Customized Synthetic Library Screening), $Billion, 2023-2035
  • Figure 22: Global Biologics Drug Discovery Market (Phage Display Screening), $Billion, 2023-2035
  • Figure 23: Global Biologics Drug Discovery Market (High-Throughput Screening), $Billion, 2023-2035
  • Figure 24: Global Biologics Drug Discovery Market (Others), $Billion, 2023-2035
  • Figure 25: Global Biologics Drug Discovery Market (Lead Identification), $Billion, 2023-2035
  • Figure 26: Global Biologics Drug Discovery Market (Phage Display), $Billion, 2023-2035
  • Figure 27: Global Biologics Drug Discovery Market (ELISA/ADCC and CDC Assay), $Billion, 2023-2035
  • Figure 28: Global Biologics Drug Discovery Market (Array-Based Screening), $Billion, 2023-2035
  • Figure 29: Global Biologics Drug Discovery Market (Hybridoma Screening and Humanization), $Billion, 2023-2035
  • Figure 30: Global Biologics Drug Discovery Market (Bioanalytical Analysis), $Billion, 2023-2035
  • Figure 31: Global Biologics Drug Discovery Market (Other Assays), $Billion, 2023-2035
  • Figure 32: Global Biologics Drug Discovery Market (Lead Optimization), $Billion, 2023-2035
  • Figure 33: Global Biologics Drug Discovery Market (Humanization), $Billion, 2023-2035
  • Figure 34: Global Biologics Drug Discovery Market (Affinity Analysis), $Billion, 2023-2035
  • Figure 35: Global Biologics Drug Discovery Market (Protein Engineering), $Billion, 2023-2035
  • Figure 36: Global Biologics Drug Discovery Market (In-Vitro/In-Vivo Efficacy Assays), $Billion, 2023-2035
  • Figure 37: Global Biologics Drug Discovery Market (Others), $Billion, 2023-2035
  • Figure 38: Global Biologics Drug Discovery Market (by Manufacturing Type), $Billion, 2025, 2029, and 2035
  • Figure 39: Global Biologics Drug Discovery Market (In-House Manufacturing), $Billion, 2023-2035
  • Figure 40: Advantages of Outsourcing Drug Development Operations
  • Figure 41: Global Biologics Drug Discovery Market (Outsourced Manufacturing), $Billion, 2023-2035
  • Figure 42: Global Biologics Drug Discovery Market (by Type), $Billion, 2025, 2029, and 2035
  • Figure 43: Global Biologics Drug Discovery Market (Monoclonal Antibodies), $Billion, 2023-2035
  • Figure 44: Global Biologics Drug Discovery Market (Recombinant Proteins), $Billion, 2023-2035
  • Figure 45: Global Biologics Drug Discovery Market (Other Biologics), $Billion, 2023-2035
  • Figure 46: North America Biologics Drug Discovery Market, $Billion, 2023-2035
  • Figure 47: U.S. Biologics Drug Discovery Market, $Billion, 2023-2035
  • Figure 48: Canada Biologics Drug Discovery Market, $Billion, 2023-2035
  • Figure 49: Europe Biologics Drug Discovery Market, $Billion, 2023-2035
  • Figure 50: Germany Biologics Drug Discovery Market, $Billion, 2023-2035
  • Figure 51: U.K. Biologics Drug Discovery Market, $Billion, 2023-2035
  • Figure 52: France Biologics Drug Discovery Market, $Billion, 2023-2035
  • Figure 53: Italy Biologics Drug Discovery Market, $Billion, 2023-2035
  • Figure 54: Spain Biologics Drug Discovery Market, $Billion, 2023-2035
  • Figure 55: Rest-of-Europe Biologics Drug Discovery Market, $Billion, 2023-2035
  • Figure 56: Asia-Pacific Biologics Drug Discovery Market, $Billion, 2023-2035
  • Figure 57: China Biologics Drug Discovery Market, $Billion, 2023-2035
  • Figure 58: Japan Biologics Drug Discovery Market, $Billion, 2023-2035
  • Figure 59: India Biologics Drug Discovery Market, $Billion, 2023-2035
  • Figure 60: South Korea Biologics Drug Discovery Market, $Billion, 2023-2035
  • Figure 61: Australia Biologics Drug Discovery Market, $Billion, 2023-2035
  • Figure 62: Rest-of-Asia-Pacific Biologics Drug Discovery Market, $Billion, 2023-2035
  • Figure 63: Rest-of-the-World Biologics Drug Discovery Market, $Billion, 2023-2035
  • Figure 64: Data Triangulation
  • Figure 65: Top-Down and Bottom-Up Approach
  • Figure 66: Assumptions and Limitations

List of Tables

  • Table 1: Market Snapshot
  • Table 2: Global Biologics Drug Discovery Market, Key Market Trends
  • Table 3: Key Partnerships in the Biologics Drug Discovery Market
  • Table 4: Market Dynamics
  • Table 5: Monoclonal Antibodies Drug Discovery Market (by Method), $Billion, 2023-2035
  • Table 6: Monoclonal Antibodies Drug Discovery Market, (by Method, Target Identification/Validation), $Billion, 2023-2035
  • Table 7: Monoclonal Antibodies Drug Discovery Market, (by Method, Hit Generation/Validation), $Billion, 2023-2035
  • Table 8: Monoclonal Antibodies Drug Discovery Market, (by Method, Lead Identification), $Billion, 2023-2035
  • Table 9: Monoclonal Antibodies Drug Discovery Market, (by Method, Lead Optimization), $Billion, 2023-2035
  • Table 10: Recombinant Proteins Drug Discovery Market (by Method), $Billion, 2023-2035
  • Table 11: Recombinant Proteins Drug Discovery Market, (by Method, Target Identification/Validation), $Billion, 2023-2035
  • Table 12: Recombinant Proteins Drug Discovery Market, (by Method, Hit Generation/Validation), $Billion, 2023-2035
  • Table 13: Recombinant Proteins Drug Discovery Market, (by Method, Lead Identification), $Billion, 2023-2035
  • Table 14: Recombinant Proteins Drug Discovery Market, (by Method, Lead Optimization), $Billion, 2023-2035
  • Table 15: Global Biologics Drug Discovery Market (by Region), $Billion, 2023-2035
  • Table 16: North America Biologics Drug Discovery Market (by Manufacturing Type), $Billion, 2023-2035
  • Table 17: North America Biologics Drug Discovery Market (by Type), $Billion, 2023-2035
  • Table 18: North America Biologics Drug Discovery Market (by Country), $Billion, 2023-2035
  • Table 19: U.S. Biologics Drug Discovery Market (by Manufacturing Type), $Billion, 2023-2035
  • Table 20: U.S. Biologics Drug Discovery Market (by Type), $Billion, 2023-2035
  • Table 21: Canada Biologics Drug Discovery Market (by Manufacturing Type), $Billion, 2023-2035
  • Table 22: Canada Biologics Drug Discovery Market (by Type), $Billion, 2023-2035
  • Table 23: Europe Biologics Drug Discovery Market (by Manufacturing Type), $Billion, 2023-2035
  • Table 24: Europe Biologics Drug Discovery Market (by Type), $Billion, 2023-2035
  • Table 25: Europe Biologics Drug Discovery Market (by Country), $Billion, 2023-2035
  • Table 26: Germany Biologics Drug Discovery Market (by Manufacturing Type), $Billion, 2023-2035
  • Table 27: Germany Biologics Drug Discovery Market (by Type), $Billion, 2023-2035
  • Table 28: U.K. Biologics Drug Discovery Market (by Manufacturing Type), $Billion, 2023-2035
  • Table 29: U.K. Biologics Drug Discovery Market (by Type), $Billion, 2023-2035
  • Table 30: France Biologics Drug Discovery Market (by Manufacturing Type), $Billion, 2023-2035
  • Table 31: France Biologics Drug Discovery Market (by Type), $Billion, 2023-2035
  • Table 32: Italy Biologics Drug Discovery Market (by Manufacturing Type), $Billion, 2023-2035
  • Table 33: Italy Biologics Drug Discovery Market (by Type), $Billion, 2023-2035
  • Table 34: Spain Biologics Drug Discovery Market (by Manufacturing Type), $Billion, 2023-2035
  • Table 35: Spain Biologics Drug Discovery Market (by Type), $Billion, 2023-2035
  • Table 36: Rest-of-Europe Biologics Drug Discovery Market (by Manufacturing Type), $Billion, 2023-2035
  • Table 37: Rest-of-Europe Biologics Drug Discovery Market (by Type), $Billion, 2023-2035
  • Table 38: Asia-Pacific Biologics Drug Discovery Market (by Manufacturing Type), $Billion, 2023-2035
  • Table 39: Asia-Pacific Biologics Drug Discovery Market (by Type), $Billion, 2023-2035
  • Table 40: Asia-Pacific Biologics Drug Discovery Market (by Country), $Billion, 2023-2035
  • Table 41: China Biologics Drug Discovery Market (by Manufacturing Type), $Billion, 2023-2035
  • Table 42: China Biologics Drug Discovery Market (by Type), $Billion, 2023-2035
  • Table 43: Japan Biologics Drug Discovery Market (by Manufacturing Type), $Billion, 2023-2035
  • Table 44: Japan Biologics Drug Discovery Market (by Type), $Billion, 2023-2035
  • Table 45: India Biologics Drug Discovery Market (by Manufacturing Type), $Billion, 2023-2035
  • Table 46: India Biologics Drug Discovery Market (by Type), $Billion, 2023-2035
  • Table 47: South Korea Biologics Drug Discovery Market (by Manufacturing Type), $Billion, 2023-2035
  • Table 48: South Korea Biologics Drug Discovery Market (by Type), $Billion, 2023-2035
  • Table 49: Australia Biologics Drug Discovery Market (by Manufacturing Type), $Billion, 2023-2035
  • Table 50: Australia Biologics Drug Discovery Market (by Type), $Billion, 2023-2035
  • Table 51: Rest-of-Asia-Pacific Biologics Drug Discovery Market (by Manufacturing Type), $Billion, 2023-2035
  • Table 52: Rest-of-Asia-Pacific Biologics Drug Discovery Market (by Type), $Billion, 2023-2035
  • Table 53: Rest-of-the-World Biologics Drug Discovery Market (by Manufacturing Type), $Billion, 2023-2035
  • Table 54: Rest-of-the-World Biologics Drug Discovery Market (by Type), $Billion, 2023-2035
  • Table 55: Some of the Major Key Strategies: Funding Activities, January 2022 - September 2025
  • Table 56: Some of the Major Key Strategies: Mergers and Acquisitions, January 2022 - September 2025
  • Table 57: Some of the Major Key Strategies: Regulatory Approvals and Product Launches, January 2022 - September 2025
  • Table 58: Some of the Major Key Strategies: Partnerships, Collaborations, and Business Expansions, January 2022 - September 2025